Stephanie Garrett, PA
Physician Assistant · Porter, OKNPI 1821482811
Payments from drug & device makers
Across 104 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$729
- AstraZeneca$454
- Lilly USA, LLC$196
- GSK$180
- Medtronic$155
- Organon$128
- plus $648 from 15 others
What the payments were for
- Food & beverage$2,489100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $729 |
| AstraZeneca | 7 | $454 |
| Lilly USA, LLC | 10 | $196 |
| GSK | 3 | $180 |
| Medtronic | 1 | $155 |
| Organon | 8 | $128 |
| Genentech USA, Inc. | 1 | $111 |
| Otsuka America Pharmaceutical, Inc. | 1 | $85 |
| Novo Nordisk | 5 | $82 |
| Astellas Pharma US Inc | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Novartis | 3 | $52 |
| Pfizer | 2 | $46 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Intra-sana Laboratories | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$362
- VRAYLAR$242
- SIMPLERA SENSOR$155
- Xofluza$111
- TRELEGY ELLIPTA$108
How this compares
$2,489 in reported general payments places this provider in the 80th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 85 | $120,760 |
| Dupixent PenDupilumab | 17 | $74,984 |
| MounjaroTirzepatide | 46 | $68,963 |
| OzempicSemaglutide | 53 | $62,698 |
| EliquisApixaban | 48 | $60,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $53,145 |
| FarxigaDapagliflozin Propanediol | 34 | $43,772 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,334 |
| JardianceEmpagliflozin | 26 | $36,237 |
| JanuviaSitagliptin Phosphate | 17 | $23,130 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $20,130 |
| MyrbetriqMirabegron | 25 | $19,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,612 |
| VraylarCariprazine Hcl | 13 | $18,419 |
| XareltoRivaroxaban | 14 | $17,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $196 | $189,723131 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $454 | $73,17284 claims |
| PfizerEliquis, Premarin | $46 | $67,94064 claims |
| Novo NordiskOzempic | $82 | $62,69853 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $61,83844 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $14 | $55,64525 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $19,29625 claims |
| AbbVieVraylar | $729 | $18,41913 claims |
| NovartisEntresto | $52 | $16,67513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Porter
- Eric CampbellEdmond$246K
- Katherine DemersEl Reno$146K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
- Muge ParkTulsa$17K
- Rose RamirezTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.